Novel FabH inhibitors: an updated article literature review (July 2012 to June 2013)

Bibliography

• Leeb M. A shot in the arm. Nature 2004;431:892-3
   PubMed Web of Science ®Google Scholar
• Cronan JE Jr, Rock CO. In escherichia coli and salmonella typhimurium: cellular and molecular biology. In: Neidhardt FC. Escherichia coli and salmonella typhimurium: cellular and molecular biology. ASM Press, Washington, D.C.; 1996
   Google Scholar
• Lai CY, Cronan JE. β-ketoacyl-acyl carrier protein synthase III (FabH) is essential for bacterial fatty acid synthesis. J Biol Chem 2003;19:51494-503
   Google Scholar
• Lu YJ, Zhang YM, Rock CO. Product diversity and regulation of type II fatty acid synthases. Biochem Cell Biol 2004;82:145-55
   PubMedGoogle Scholar
• Jayakumar A, Tai MH, Huang WY, et al. Human fatty acid synthase: properties and molecular cloning. J Proc Natl Acad. Sci 1995;92:8695-9
   PubMed Web of Science ®Google Scholar
• White SW, Zheng J, Zhang YM, et al. The structural biology of type II fatty acid biosynthesis. Annu Rev Biochem 2005;74:791-831
   PubMed Web of Science ®Google Scholar
• Veyron-Churlet R, Guerrini O, Mourey L, et al. Protein-protein interactions within the FAS-II system of mycobacterium tuberculosis: a new prospect in anti-tuberculosis drug discovery. Mol Microbiol 2004;54:1161-72
   PubMedGoogle Scholar
• Jr Cronan JE, Waldrop GL. Multi-subunit acetyl-CoA carboxylases. Prog Lipid Res 2002;41:407-35
   PubMedGoogle Scholar
• Serre L, Verbree EC, Dauter Z, et al. The escherichia coli malonyl-CoA: acyl carrier protein transacylase at 1.5-Å resolution. J Biol Chem 1995;270:12961-4
   PubMed Web of Science ®Google Scholar
• Jackowski S, Rock CO. Acetoacetyl-acyl carrier protein synthase, a potential regulator of fatty acid biosynthesis in bacteria. J Biol Chem 1987;262:7927-31
   PubMedGoogle Scholar
• Heath RJ, Rock CO. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in escherichia coli. J Biol Chem 1995;270:26538-42
   PubMed Web of Science ®Google Scholar
• Heath RJ, Rock CO. Roles of the FabA and FabZ beta-hydroxyacyl-acyl carrier protein dehydratases in escherichia coli Fatty acid biosynthesis. J Biol Chem 1996;271:27795-801
   PubMed Web of Science ®Google Scholar
• Bergler H, Wallner P, Ebeling A, et al. Protein EnvM is the NADH-dependent enoyl- ACP reductase (FabI) of escherichia coli. J Biol Chem 1994;269:5493-6
   PubMed Web of Science ®Google Scholar
• Tsay JT, Oh W, Larson TJ, et al. Isolation and characterization of the beta-ketoacyl-acyl carrier protein synthase III gene (fabH) from escherichia coli K-12. J Biol Chem 1992;267:6807-14
   PubMed Web of Science ®Google Scholar
• Garwin JL, Klages AL, Cronan JE Jr. Structural, enzymatic, and genetic studies of beta- ketoacyl-acyl carrier protein synthases I and II of escherichia coli. J Biol Chem 1980;255:11949-56
   PubMedGoogle Scholar
• Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of FabI inhibitors. US0510400; 2013
   Google Scholar
• Affinium Pharmaceuticals, Inc. FabI inhibitors. US8173646; 2012
   Google Scholar
• Affinium Pharmaceuticals, Inc. FabI inhibitors. US8153652; 2012
   Google Scholar
• Christensen CE, Kragelund BB, von Wettstein-Knowles P, et al. Structure of the human β-ketoacyl [ACP] synthase from the mitochondrial type II fatty acid synthase. Protein Sci 2007;16:261-72
   PubMedGoogle Scholar
• Bylka W, Matlawska I, Pilewski NA. Natural flavonoids as antimicrobial agents. JANA 2004;7:24-31
   Google Scholar
• Li HQ, Shi L, Li QS, et al. Synthesis of C(7) modified chrysin derivatives designing to inhibit β-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics. Bioorg Med Chem 2009;17:6264-9
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang YS, Fu J, et al. Novel FabH inhibitors: a patent and article literature review (2000 – 2012). Expert Opin Ther Patents 2012;11:1325-36
   Google Scholar
• Lee J, Jeong K, Lee J, et al. Novel E. coli β-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics. Bioorg Med Chem 2009;17:1506-13
   PubMed Web of Science ®Google Scholar
• Zhou Y, Du QR, Sun J, et al. Novel schiff-base-derived FabH inhibitors with dioxygenated rings as antibiotic agents. Chem Med Chem 2013;8:433-41
   Google Scholar
• Parthiban P, Aridoss G, Rathika P, et al. Synthesis, stereochemistry and antimicrobial studies of novel oxime ethers of aza/diazabicycles. Bioorg Med Chem Lett 2009;19:6981-5
   PubMedGoogle Scholar
• Parthiban P, Kabilan S, Ramkumar V, et al. Stereocontrolled facile synthesis and antimicrobial activity of oximes and oxime ethers of diversely substituted bispidines. Bioorg Med Chem Lett 2010;20:6452-8
   PubMedGoogle Scholar
• Bhandari K, Srinivas N, Shiva Keshava GB, et al. Tetrahydronaphthyl azole oxime ethers: the conformationally rigid analogues of oxiconazole as antibacterials. Eur J Med Chem 2009;44:437-47
   PubMed Web of Science ®Google Scholar
• Emami S, Falahati M, Banifatemi A, et al. Stereoselective synthesis and antifungal activity of (Z)-trans-3-azolyl-2-methylchromanone oxime ethers. Bioorg Med Chem 2004;12:5881-9
   PubMed Web of Science ®Google Scholar
• Li HQ, Xiao ZP, Luo Y, et al. Amines and oximes derived from deoxybenzoins as helicobacter pyloriurease inhibitors. Eur J Med Chem 2009;44:2246-51
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhang LR, Hu Y, et al. Synthesis and antimicrobial activities of oximes derived from O-benzylhydroxylamine as FabH inhibitors. Chem Med Chem 2012;7:1587-93
   Google Scholar
• Lv PC, Wang KR, Yang Y, et al. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors. Bioorg Med Chem Lett 2009;19:6750-4
   PubMed Web of Science ®Google Scholar
• Li HQ, Luo Y, Lv PC, et al. Design and synthesis of novel deoxybenzoin derivatives as FabH inhibitors and anti-inflammatory agents. Bioorg Med Chem Lett 2010;20:2025-8
   PubMed Web of Science ®Google Scholar
• Shi L, Fang RQ, Zhu ZW, et al. Design and synthesis of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III (FabH) as potential antibacterial agents. Eur J Med Chem 2010;45:4358-64
   PubMedGoogle Scholar
• Cheng K, Zheng QZ, Qian Y, et al. Synthesis, antibacterial activities and molecular docking studies of peptide and schiff bases as targeted antibiotics. Bioorg Med Chem 2009;17:7861-71
   PubMed Web of Science ®Google Scholar
• Lv PC, Sun J, Luo Y, et al. Design, synthesis, and structure–activity relationships of pyrazole derivatives as potential FabH inhibitors. Bioorg Med Chem Lett 2010;20:4657-60
   PubMed Web of Science ®Google Scholar
• Lee JY, Jeong KW, Lee JU, et al. Novel E. coli β-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics. Bioorg Med Chem 2009;17:1506-13
   PubMed Web of Science ®Google Scholar
• Lee JY, Jeong KW, Shin S, et al. Discovery of novel selective inhibitors of Staphylococcus aureus β-ketoacyl acyl carrier protein synthase III. Eur J Med Chem 2012;47:261-9
   PubMedGoogle Scholar
• Kamel AM, Lobna MA, El-Sayed ML, et al. Synthesis, characterization, antimicrobial activity and structure-activity relationships of new aryldisulfonamides. Bioorg Med Chem 2006;14:8675-82
   PubMed Web of Science ®Google Scholar
• Wang XL, Zhang YB, Tang JF, et al. Design, synthesis and antibacterial activities of vanillic acylhydrazone derivatives as potential β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. Eur J Med Chem 2012;57:373-82
   PubMed Web of Science ®Google Scholar
• Hu Y, Lu X, Chen K, et al. Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents. Bioorg Med Chem 2012;20:903-9
   PubMed Web of Science ®Google Scholar
• Dolman SJ, Gosselin F, Oshea PD, et al. Superior reactivity of thiosemicarbazides in the synthesis of 2-amino-1, 3, 4-oxadiazoles. J Org Chem 2006;71:9548-51
   PubMed Web of Science ®Google Scholar
• Chen CJ, Song BA, Yang S, et al. Synthesis and antifungal activities of 5-(3,4,5- trimethoxyphenyl)-2-sulfonyl-1,3,4-thiadiazole and 5-(3,4,5-trimethoxyphenyl)-2-sulfonyl- 1,3,4-oxadiazole derivatives. Bioorg Med Chem 2007;15:3981-9
   PubMed Web of Science ®Google Scholar
• Luo YP, Yang GF. Discovery of a new insecticide lead by optimizing a target-diverse scaffold: tetrazolinone derivatives. Bioorg Med Chem 2007;15:1716-24
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang ZM, Fang XY, et al. Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents. Bioorg Med Chem 2012;20:1373-9
   PubMed Web of Science ®Google Scholar
• Ono Phamaceutical Co. Ltd. Indole compounds for treating respiratory disorders. EP1852420; 2012
   Google Scholar
• Li Y, Luo Y, Hu Y, et al. Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4- oxadiazole scaffold as FabH inhibitors. Bioorg Med Chem 2012;20:4316-22
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao CP, Ma HP, et al. Design, synthesis and antimicrobial activities evaluation of Schiff base derived from secnidazole derivatives as potential FabH inhibitors. Bioorg Med Chem 2013;21:3120-6
   PubMed Web of Science ®Google Scholar
• Choi KH, Kremer L, Besra GS, et al. Identification and substrate specificity of b-ketoacyl (Acyl Carrier Protein) synthase III (mtFabH) from Mycobacterium tuberculosis. J Biol Chem 2000;275:28201-7
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhong W, Li RJ, et al. Synthesis of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. Molecules 2012;17:4770-81
   PubMedGoogle Scholar
• Jones PB, Parrish NM, Houston TA, et al. A new class of antituberculosis agents. J Med Chem 2000;43:3304-14
   PubMed Web of Science ®Google Scholar
• Khandekar SS, Gentry DR, Van Aller GS, et al. Identification, substrate specificity, and inhibition of the streptococcus pneumoniae beta-ketoacylacyl carrier protein synthase III (FabH). J Biol Chem 2001;276:30024-30
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Antibiotic compound. EP1756034; 2005
   Google Scholar
• Chung MC, Ferreira EI, Santos JL, et al. Prodrugs for the treatment of neglected diseases. Molecule 2008;13:616-77
   Web of Science ®Google Scholar
• Tanitame A, Oyamada Y, Ofuji K, et al. Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J Med Chem 2004;47:3693-6
   PubMed Web of Science ®Google Scholar
• Genin MJ, Allwine DA, Anderson DJ, et al. Substituent effects on the antibacterial activity of nitrogen−carbon-linked (azolylphenyl) oxazolidinones with expanded activity against the fastidious Gram-negative organisms Haemophilus influenza and Moraxella catarrhalis. J Med Chem 2000;43:953-70
   PubMed Web of Science ®Google Scholar
• Bekhit AA, Fahmy HTY, Rostom SAF, et al. Design and synthesis of some substituted 1H-pyrazolyl-thiazolo[4,5-d]pyrimidines as anti-inflammatory antimicrobial agents. Eur J Med Chem 2003;38:27-36
   PubMed Web of Science ®Google Scholar
• Chimenti F, Bizzarri B, Bolasco A, et al. Synthesis and biological evaluation of novel 2,4-disubstituted-1,3-thiazoles as anti-Candida spp. agents. Eur J Med Chem 2011;46:378-82
   PubMed Web of Science ®Google Scholar
• Lv PC, Zhou CF, Chen J, et al. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. Bioorg Med Chem 2010;18:314-19
   PubMed Web of Science ®Google Scholar
• Yang YS, Zhang F, Gao C, et al. Discovery and modification of sulfur-containing heterocyclic pyrazoline derivatives as potential novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors. Bioorg Med Chem Lett 2012;22:4619-24
   PubMedGoogle Scholar
• Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthetase inhibitors. Science 2000;288:2379-81
   PubMed Web of Science ®Google Scholar
• Daines RA, Pendrak I, Sham K, et al. First X-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J Med Chem 2003;46:5-8
   PubMed Web of Science ®Google Scholar
• Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram- positive pathogens. Nature 2009;458:83-6
   PubMed Web of Science ®Google Scholar